This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
acute respiratory | 164 |
respiratory tract | 134 |
influenza virus | 90 |
severe acute | 87 |
virus infection | 86 |
respiratory syncytial | 85 |
syncytial virus | 83 |
respiratory syndrome | 79 |
intensive care | 76 |
pseudomonas aeruginosa | 74 |
novel coronavirus | 69 |
respiratory viruses | 67 |
risk factors | 61 |
immunocompromised patients | 59 |
critically ill | 57 |
infect dis | 56 |
care unit | 55 |
microbiol infect | 55 |
clin microbiol | 53 |
septic shock | 53 |
rna detection | 53 |
dis doi | 53 |
doc id | 53 |
cord uid | 53 |
pulmonary syndrome | 53 |
chain reaction | 52 |
polymerase chain | 52 |
ill patients | 51 |
hospital admission | 50 |
respiratory failure | 49 |
coronavirus disease | 49 |
respiratory distress | 49 |
tract infections | 47 |
mechanical ventilation | 44 |
hantavirus pulmonary | 44 |
acinetobacter baumannii | 42 |
herpes simplex | 40 |
viral rna | 40 |
acquired pneumonia | 38 |
poor outcome | 38 |
statistically significant | 37 |
staphylococcus aureus | 37 |
simplex virus | 37 |
regression analysis | 36 |
hospitalized patients | 35 |
clinical features | 35 |
time pcr | 35 |
human bocavirus | 35 |
hydrogen peroxide | 35 |
clinical characteristics | 35 |
cohort study | 34 |
informed consent | 33 |
distress syndrome | 33 |
viral infections | 33 |
median age | 33 |
one patient | 33 |
day pos | 33 |
significantly higher | 32 |
lower respiratory | 32 |
respiratory symptoms | 32 |
among patients | 32 |
blood culture | 32 |
tested positive | 31 |
antibiotic use | 31 |
respiratory samples | 30 |
present study | 30 |
copies ml | 30 |
lung injury | 30 |
control group | 30 |
pg ml | 29 |
clinical outcome | 29 |
nic patients | 29 |
systematic review | 29 |
tract infection | 29 |
public health | 29 |
renal failure | 29 |
symptom score | 29 |
world health | 29 |
respiratory virus | 28 |
upper respiratory | 28 |
health organization | 28 |
bronchoalveolar lavage | 28 |
human metapneumovirus | 28 |
respiratory infections | 28 |
logistic regression | 27 |
rhamnosus gg | 27 |
icu admission | 27 |
viral tests | 27 |
viral load | 26 |
supplementary material | 26 |
nasopharyngeal swab | 26 |
confirmed cases | 26 |
virus infections | 26 |
nucleic acid | 26 |
least one | 25 |
infection control | 25 |
ic patients | 25 |
tested drugs | 25 |
meningococcal disease | 25 |
hong kong | 25 |
influenza viruses | 24 |
authors declare | 24 |
syndrome coronavirus | 24 |
serum samples | 24 |
flocked swabs | 24 |
patients admitted | 24 |
immune response | 24 |
respiratory viral | 24 |
pcr assay | 23 |
environmental surfaces | 23 |
nasopharyngeal swabs | 23 |
two patients | 23 |
neuraminidase inhibitor | 23 |
ncov assay | 22 |
years old | 22 |
viral infection | 22 |
quorum sensing | 22 |
severe adenovirus | 22 |
united states | 22 |
case report | 22 |
study period | 22 |
study population | 21 |
performed using | 21 |
positive sars | 21 |
neuraminidase inhibitors | 21 |
respiratory infection | 21 |
severe influenza | 21 |
candida spp | 21 |
university hospital | 21 |
viral shedding | 21 |
stem cell | 21 |
baumannii isolates | 21 |
hematological abnormalities | 21 |
previously described | 21 |
renal syndrome | 21 |
mg dl | 21 |
springer nature | 20 |
continuous variables | 20 |
common cold | 20 |
institutional affiliations | 20 |
age groups | 20 |
esophageal candidiasis | 20 |
nature remains | 20 |
positive rt | 20 |
puumala virus | 20 |
remains neutral | 20 |
note springer | 20 |
jurisdictional claims | 20 |
nylon flocked | 20 |
epithelial cells | 20 |
significant difference | 20 |
relative humidity | 20 |
two groups | 20 |
retrospective study | 20 |
published maps | 20 |
coronavirus pneumonia | 19 |
community controls | 19 |
invasive pneumococcal | 19 |
immunocompetent patients | 19 |
current study | 19 |
young children | 19 |
respiratory pathogens | 19 |
respiratory disease | 19 |
infectious diseases | 19 |
cell culture | 19 |
bacterial load | 19 |
clinical trials | 19 |
bacterial meningitis | 19 |
patients without | 19 |
care units | 18 |
statistical analysis | 18 |
positive patients | 18 |
adult patients | 18 |
influenza infection | 18 |
conjugate vaccine | 18 |
bacterial infections | 18 |
multiplex pcr | 18 |
acute renal | 18 |
respiratory illness | 18 |
health care | 18 |
icu patients | 18 |
clinical course | 18 |
previous studies | 17 |
disease control | 17 |
interquartile range | 17 |
disease severity | 17 |
ev rna | 17 |
combination therapy | 17 |
asymptomatic children | 17 |
kidney injury | 17 |
pcr test | 17 |
significantly associated | 17 |
clinical practice | 17 |
controlled trial | 17 |
hemorrhagic fever | 16 |
nose inoculation | 16 |
chest ct | 16 |
infected patients | 16 |
antibiotic resistance | 16 |
clinical symptoms | 16 |
viral respiratory | 16 |
antibiotic therapy | 16 |
prospective study | 16 |
inappropriate antibiotic | 16 |
acute kidney | 16 |
hospital environment | 16 |
virulence factors | 16 |
least two | 16 |
ethics committee | 16 |
symptomatic patients | 15 |
mean age | 15 |
reverse transcriptase | 15 |
mxa protein | 15 |
human immunodeficiency | 15 |
previous reports | 15 |
antiviral treatment | 15 |
reverse transcription | 15 |
nephropathia epidemica | 15 |
hantavirus infection | 15 |
nucleic acids | 15 |
immunodeficiency virus | 15 |
mean temperature | 15 |
invasive aspergillosis | 15 |
delayed hospital | 15 |
resistant influenza | 15 |
acute lung | 14 |
exact test | 14 |
retrospective cohort | 14 |
contains supplementary | 14 |
oxidative stress | 14 |
viral etiology | 14 |
symptoms onset | 14 |
risk factor | 14 |
patients presented | 14 |
ct values | 14 |
parainfluenza virus | 14 |
applied biosystems | 14 |
online version | 14 |
blood cultures | 14 |
transplant recipients | 14 |
associated pneumonia | 14 |
iaa patients | 14 |
ethical approval | 14 |
corticosteroid treatment | 14 |
sample size | 14 |
significant differences | 14 |
rayon swabs | 14 |
central nervous | 14 |
predictive value | 14 |
organ dysfunction | 14 |
pneumococcal pneumonia | 14 |
virus type | 14 |
young adults | 14 |
environmental contamination | 14 |
avian influenza | 13 |
pulmonary disease | 13 |
high rate | 13 |
disease burden | 13 |
type i | 13 |
resistant acinetobacter | 13 |
independent risk | 13 |
bloodstream infections | 13 |
respiratory diseases | 13 |
mortality rate | 13 |
standard deviation | 13 |
cerebrospinal fluid | 13 |
nervous system | 13 |
observational study | 13 |
resistant staphylococcus | 13 |
three patients | 13 |
pulmonary infiltrates | 13 |
rna standard | 13 |
candida albicans | 13 |
mg day | 13 |
two cases | 13 |
topoisomerase ii | 13 |
chronic obstructive | 13 |
healthcare workers | 13 |
viral pneumonia | 13 |
confirmed sars | 13 |
early hospital | 13 |
sofa score | 13 |
sars outbreak | 13 |
capsular groups | 13 |
neisseria meningitidis | 13 |
rhinovirus infection | 13 |
hemophagocytic syndrome | 13 |
computed tomography | 13 |
high mortality | 12 |
reactive protein | 12 |
pneumocystis jirovecii | 12 |
severe covid | 12 |
test results | 12 |
mean duration | 12 |
aureus bacteremia | 12 |
twitching motility | 12 |
inflammatory response | 12 |
mechanically ventilated | 12 |
common respiratory | 12 |
invasive meningococcal | 12 |
xpress sars | 12 |
pcr assays | 12 |
oseltamivir resistance | 12 |
laboratory findings | 12 |
significantly lower | 12 |
good outcome | 12 |
authorized users | 12 |
emergency department | 12 |
mg ml | 12 |
associated infections | 12 |
detection duration | 12 |
pulmonary involvement | 12 |
recovered covid | 12 |
frequently detected | 12 |
influenza patients | 12 |
seasonal influenza | 12 |
animal models | 12 |
electronic supplementary | 12 |
blood samples | 12 |
healthy volunteers | 12 |
incidence rate | 12 |
iav infection | 12 |
impaired co | 12 |
peripheral blood | 12 |
obstructive pulmonary | 12 |
multiple sclerosis | 12 |
patients received | 12 |
rti symptoms | 12 |
biofilm formation | 12 |
rsv infection | 12 |
nosocomial infections | 11 |
laboratory diagnosis | 11 |
associated motility | 11 |
four patients | 11 |
univariate analysis | 11 |
significant association | 11 |
recent study | 11 |
study protocol | 11 |
invasive mechanical | 11 |
among children | 11 |
clostridium difficile | 11 |
clinical outcomes | 11 |
positive pneumonia | 11 |
cns infections | 11 |
cell transplantation | 11 |
increased risk | 11 |
categorical variables | 11 |
cfu ml | 11 |
swarming motility | 11 |
ifng rs | 11 |
low levels | 11 |
severe respiratory | 11 |
puuv rna | 11 |
case series | 11 |
probiotic bacteria | 11 |
sars coronavirus | 11 |
severe patients | 11 |
recent years | 11 |
meningococcal carriage | 11 |
older adults | 11 |
viral replication | 11 |
pcr results | 11 |
clinical manifestations | 11 |
antibody responses | 11 |
organ failure | 11 |
bloodstream infection | 11 |
escherichia coli | 11 |
coronavirus infection | 11 |
independent variables | 11 |
direct contact | 11 |
southern china | 11 |
subpleural lesion | 11 |
influenza season | 11 |
solid organ | 11 |
glass attenuations | 10 |
lung tissues | 10 |
mg kg | 10 |
regression models | 10 |
general hospital | 10 |
like illness | 10 |
cox regression | 10 |
poor clinical | 10 |
several studies | 10 |
another study | 10 |
case definition | 10 |
serratia marcescens | 10 |
randomized controlled | 10 |
menc disease | 10 |
sunshine duration | 10 |
day care | 10 |
statistical analyses | 10 |
pneumocystis pneumonia | 10 |
plus doxycycline | 10 |
blood pressure | 10 |
early stage | 10 |
negative bacteremia | 10 |
positive control | 10 |
adenovirus pneumonia | 10 |
ng ml | 10 |
first week | 10 |
streptococcus pneumoniae | 10 |
bone marrow | 10 |
klebsiella pneumoniae | 10 |
vaccination programme | 10 |
hematopoietic stem | 10 |
rsv infections | 10 |
aseptic meningitis | 10 |
day post | 10 |
corticosteroid therapy | 10 |
complement levels | 10 |
high levels | 10 |
positive blood | 10 |
odds ratio | 10 |
median duration | 10 |
plasmodium falciparum | 10 |
bacterial pneumonia | 10 |
parainfluenza viruses | 10 |
disease prevention | 10 |
linear regression | 10 |
clinical isolates | 10 |
unfavorable outcome | 10 |
lactobacillus rhamnosus | 10 |
ifitm rs | 9 |
operating theatre | 9 |
median symptom | 9 |
pandemic influenza | 9 |
survival time | 9 |
children years | 9 |
positive respiratory | 9 |
serum sample | 9 |
oral administration | 9 |
pediatric patients | 9 |
pao fio | 9 |
study showed | 9 |
came negative | 9 |
huanan seafood | 9 |
diagnostic tests | 9 |
lung tissue | 9 |
discharged covid | 9 |
symptom onset | 9 |
selective pressure | 9 |
negative control | 9 |
national health | 9 |
ct scan | 9 |
oral thrush | 9 |
control measures | 9 |
nine patients | 9 |
within days | 9 |
clinical presentation | 9 |
european centre | 9 |
induced lung | 9 |
immune system | 9 |
children aged | 9 |
gnb group | 9 |
aspergillus spp | 9 |
two different | 9 |
human influenza | 9 |
vertical transmission | 9 |
prolonged viral | 9 |
pcr testing | 9 |
pyogenes strains | 9 |
significantly decreased | 9 |
healthy adults | 9 |
cytopathic effect | 9 |
mild influenza | 9 |
day mortality | 9 |
health commission | 9 |
seafood market | 9 |
gastrointestinal tract | 9 |
aged years | 9 |
diagnostic yield | 9 |
platelet count | 9 |
serum creatinine | 9 |
early diagnosis | 9 |
nosocomial transmission | 9 |
hmpv prevalence | 9 |
detection rate | 9 |
icu stay | 9 |
frequently observed | 9 |
adenovirus infections | 9 |
infectious disease | 9 |
new organ | 9 |
fungal infection | 9 |
highest inhibition | 9 |
time reverse | 9 |
lactobacillus casei | 9 |
type ii | 9 |
mycoplasma pneumoniae | 9 |
healthcare facilities | 9 |
antimicrobial activity | 9 |
multiple linear | 9 |
lung disease | 9 |
factors associated | 9 |
pe applied | 9 |
time polymerase | 9 |
clinical diagnosis | 9 |
nalidixic acid | 9 |
sab group | 9 |
required icu | 9 |
patients recovered | 9 |
viral antigen | 9 |
hantavirus infections | 9 |
human coronavirus | 9 |
adenovirus infection | 9 |
spike protein | 9 |
bacterial count | 9 |
tract illness | 8 |
nasopharyngeal aspirate | 8 |
two negative | 8 |
binomial logistic | 8 |
drug resistance | 8 |
outcome group | 8 |
blood flow | 8 |
supplementary table | 8 |
community control | 8 |
lung inflammation | 8 |
barr virus | 8 |
year period | 8 |
diagnostic testing | 8 |
normal range | 8 |
times higher | 8 |
mean survival | 8 |
invasive ventilation | 8 |
per year | 8 |
ag group | 8 |
cell lines | 8 |
ct value | 8 |
antimicrobial therapy | 8 |
negative predictive | 8 |
data collection | 8 |
confidence interval | 8 |
hantavirus disease | 8 |
clinical impact | 8 |
mild cases | 8 |
virus detection | 8 |
molecular docking | 8 |
restricted mean | 8 |
case fatality | 8 |
composite endpoint | 8 |
positive results | 8 |
clinical studies | 8 |
also detected | 8 |
healthy children | 8 |
without iaa | 8 |
cytokine levels | 8 |
immunocompetent adults | 8 |
leukocyte count | 8 |
meningococcal conjugate | 8 |
written informed | 8 |
serological tests | 8 |
pulmonary edema | 8 |
imd cases | 8 |
research ethics | 8 |
among hospitalized | 8 |
menb disease | 8 |
csf samples | 8 |
patients treated | 8 |
initial symptoms | 8 |
confirmed covid | 8 |
described previously | 8 |
renal involvement | 8 |
severe pneumonia | 8 |
diabetes mellitus | 8 |
otitis media | 8 |
transcriptase polymerase | 8 |
rti episodes | 8 |
qpcr targeting | 8 |
hospital mortality | 8 |
statistical significance | 8 |
normal co | 8 |
major cause | 8 |
radiographic findings | 8 |
igg antibodies | 8 |
genome equivalents | 8 |
transmission potential | 8 |
emergency room | 8 |
hubei province | 8 |
au ml | 8 |
patients infected | 8 |
menacwy vaccine | 8 |
sars patients | 8 |
positive result | 8 |
puumala hantavirus | 8 |
gene expression | 8 |
resulted positive | 8 |
upper rti | 8 |
diagnostic value | 8 |
recipient strains | 8 |
quantitative pcr | 8 |
randomly selected | 8 |
two rooms | 8 |
control study | 8 |
host cell | 8 |
hcq az | 8 |
viral nucleic | 8 |
antimicrobial resistance | 8 |
study group | 8 |
inflammatory cytokines | 8 |
clinical specimens | 8 |
acute phase | 8 |
pulmonary aspergillosis | 8 |
meteorological data | 8 |
casei dn | 8 |
mean relative | 8 |
mononuclear cells | 8 |
six patients | 8 |
active site | 8 |
cancer patients | 8 |
old patients | 8 |
united kingdom | 8 |
immune responses | 8 |
organ dysfunctions | 8 |
positive pcr | 8 |
animalis ssp | 8 |
patients aged | 8 |
negatively correlated | 8 |
previously reported | 8 |
mm hg | 7 |
human herpesvirus | 7 |
discharged patients | 7 |
lavage fluid | 7 |
syndrome caused | 7 |
disseminated intravascular | 7 |
coxiella burnetii | 7 |
reference strains | 7 |
touch surfaces | 7 |
resistant enterococci | 7 |
critical care | 7 |
eight patients | 7 |
ethics committees | 7 |
cytokine production | 7 |
viral loads | 7 |
corticosteroid use | 7 |
protein expression | 7 |
pulmonary embolism | 7 |
medical staff | 7 |
new world | 7 |
antimicrobial stewardship | 7 |
capsular group | 7 |
necrosis factor | 7 |
blood sampling | 7 |
respiratory sample | 7 |
clinical trial | 7 |
host immune | 7 |
endothelial cells | 7 |
middle east | 7 |
antibiotic treatment | 7 |
human transmission | 7 |
lactis bb | 7 |
studies reported | 7 |
rapid diagnostic | 7 |
lopinavir plus | 7 |
inanimate surfaces | 7 |
different groups | 7 |
multivariate analysis | 7 |
igg titre | 7 |
murine model | 7 |
organ supportive | 7 |
cell cultures | 7 |
invasive fungal | 7 |
viral pathogens | 7 |
fio ratio | 7 |
significantly reduced | 7 |
using real | 7 |
notified cases | 7 |
amino acid | 7 |
antiviral effects | 7 |
room temperature | 7 |
medical history | 7 |
swab sample | 7 |
inclusion criteria | 7 |
large number | 7 |
ethical standards | 7 |
commercially available | 7 |
small sample | 7 |
patients presenting | 7 |
ten patients | 7 |
hospital stay | 7 |
antiviral activity | 7 |
square test | 7 |
upper rtis | 7 |
dna topoisomerases | 7 |
gmk ah | 7 |
neutrophil count | 7 |
reported symptoms | 7 |
review board | 7 |
developed fever | 7 |
immunosuppressed patients | 7 |
confirmed influenza | 7 |
arterial pressure | 7 |
metapneumovirus infection | 7 |
late stage | 7 |
potential qsis | 7 |
care facilities | 7 |
molecular detection | 7 |
controlled study | 7 |
chronic hepatitis | 7 |
immunosorbent assay | 7 |
confirmed pneumonia | 7 |
prognostic factors | 7 |
receptor binding | 7 |
agar plates | 7 |
prolonged sars | 7 |
east respiratory | 7 |
case definitions | 7 |
probiotic lactobacillus | 7 |
helicase activity | 7 |
reported previously | 7 |
apache ii | 7 |
consensus conference | 7 |
control groups | 7 |
fluid overload | 7 |
log pfu | 7 |
infections caused | 7 |
considered statistically | 7 |
negative bacteria | 7 |
sectional study | 7 |
time point | 7 |
nasopharyngeal samples | 7 |
consciousness disturbance | 7 |
also observed | 7 |
positive selection | 7 |
time rt | 7 |
lb broth | 7 |
transport medium | 7 |
indirect immunofluorescence | 7 |
medical equipment | 7 |
general population | 7 |
monoclonal antibody | 7 |
may also | 7 |
patients may | 7 |
severe cases | 7 |
cdna synthesis | 7 |
niv use | 7 |
negative controls | 7 |
sars cases | 7 |
hospitalized children | 7 |
significantly greater | 7 |
invasive pulmonary | 7 |
severely ill | 7 |
independently associated | 7 |
organ transplant | 7 |
patients tested | 7 |
radiological findings | 7 |
higher mortality | 7 |
log cfu | 7 |
acquired bacteraemia | 7 |
illness onset | 7 |
radiologically confirmed | 7 |
environmental cleaning | 7 |
antiviral therapy | 7 |
transcranial doppler | 7 |
consecutive days | 7 |
ethical committee | 7 |
allele frequencies | 7 |
receiver operating | 6 |
adult respiratory | 6 |
results revealed | 6 |
nucleocapsid protein | 6 |
susceptibility testing | 6 |
results obtained | 6 |
high prevalence | 6 |
performed according | 6 |
candida esophagitis | 6 |
controlled trials | 6 |
airborne transmission | 6 |
elevated levels | 6 |
imipenem resistance | 6 |
five patients | 6 |
influenza pandemic | 6 |
virus challenge | 6 |
immunocompromised adults | 6 |
positive balf | 6 |
hsv strains | 6 |
hepa units | 6 |
interstitial infiltrates | 6 |
hematological abnormality | 6 |
time analysis | 6 |
one study | 6 |
detection rates | 6 |
single detection | 6 |
quality control | 6 |
competing interests | 6 |
bal fluid | 6 |
fatal cases | 6 |
survival group | 6 |
pdm infection | 6 |
chest radiograph | 6 |
iav group | 6 |
holding method | 6 |
higher viral | 6 |
associated hemophagocytic | 6 |
small number | 6 |
fungal infections | 6 |
one virus | 6 |
disease outcome | 6 |
dna topoisomerase | 6 |
viruses among | 6 |
systemic corticosteroids | 6 |
readily available | 6 |
old man | 6 |
renal function | 6 |
cerebral blood | 6 |
increasing evidence | 6 |
replication yields | 6 |
affiliations key | 6 |
median level | 6 |
pcr inhibitors | 6 |
hand hygiene | 6 |
nosocomial infection | 6 |
without cytopenias | 6 |
analysis showed | 6 |
virus strains | 6 |
children admitted | 6 |
uv light | 6 |
creative commons | 6 |
healthcare settings | 6 |
took place | 6 |
sodium hypochlorite | 6 |
pcr products | 6 |
first time | 6 |
virus replication | 6 |
immunofluorescence assay | 6 |
results showed | 6 |
lasso analysis | 6 |
protein content | 6 |
observational studies | 6 |
aeruginosa pao | 6 |
broad range | 6 |
falciparum malaria | 6 |
discriminate pcp | 6 |
fatality rate | 6 |
multiplex real | 6 |
time quantitative | 6 |
hps cases | 6 |
first day | 6 |
abai gene | 6 |
influenza vaccination | 6 |
advanced age | 6 |
pj qpcr | 6 |
pneumonia among | 6 |
pfu lds | 6 |
relatively small | 6 |
rhamnolipid production | 6 |
three ict | 6 |
new positive | 6 |
gastrointestinal symptoms | 6 |
adjusted hr | 6 |
tumor necrosis | 6 |
elderly patients | 6 |
winter season | 6 |
igg igm | 6 |
increased levels | 6 |
virus types | 6 |
samples collected | 6 |
antibody response | 6 |
air samples | 6 |
quantitative real | 6 |
group vs | 6 |
ii topoisomerases | 6 |
tertiary care | 6 |
sas institute | 6 |
supportive therapies | 6 |
tested negative | 6 |
respiratory specimens | 6 |
rapid detection | 6 |
renal impairment | 6 |
conjugate vaccines | 6 |
better understanding | 6 |
transcription polymerase | 6 |
urine output | 6 |
laboratory results | 6 |
chlamydia pneumoniae | 6 |
antimicrobial surfaces | 6 |
operating characteristic | 6 |
linked immunosorbent | 6 |
study included | 6 |
response genes | 6 |
healthcare environment | 6 |
acid extraction | 6 |
inflammatory cns | 6 |
invasive candidiasis | 6 |
direct protection | 6 |
old woman | 6 |
showed higher | 6 |
pj colonization | 6 |
infection due | 6 |
lb agar | 6 |
multivariate cox | 6 |
life technologies | 6 |
negative rt | 6 |
positive predictive | 6 |
ventilatory support | 6 |
predisposing factors | 6 |
randomised controlled | 6 |
showed bilateral | 6 |
internal control | 6 |
acquired bacteraemias | 6 |
previous study | 6 |
sample collection | 6 |
mean bacterial | 6 |
contact transmission | 6 |
median levels | 6 |
treated patients | 6 |
higher risk | 6 |
exclusion criteria | 6 |
attack rate | 6 |
menw disease | 6 |
positive cases | 6 |
copies reaction | 6 |
hospitalized controls | 6 |
trial version | 6 |
seasonal distribution | 6 |
clinical picture | 6 |
bk virus | 6 |
negative results | 6 |
also included | 6 |
newly recognized | 6 |
clinical findings | 6 |
disease caused | 6 |
cell activity | 6 |
patient care | 6 |
detected pathogens | 6 |
clinical management | 6 |
mortality associated | 6 |
hiv infection | 6 |
immunosuppressive therapy | 6 |
possible pcp | 6 |
probable sars | 6 |
group without | 6 |
among adults | 6 |
prima professional | 6 |
aspergillus fumigatus | 6 |
complete genome | 6 |
dendritic cells | 6 |
three times | 6 |
desirable outcome | 6 |
much higher | 6 |
severe ivi | 6 |
increased mortality | 6 |
study design | 6 |
hospital discharge | 6 |
amino acids | 6 |
cell transplant | 6 |
meningococcal serogroup | 6 |
good clinical | 6 |
days post | 6 |
probiotic strains | 6 |
higher prevalence | 6 |
confidence intervals | 6 |
mycobacterium tuberculosis | 6 |
pcp group | 6 |
pneumococcal disease | 6 |
incidence rates | 5 |
old world | 5 |
whole genome | 5 |
previously healthy | 5 |
year study | 5 |
low prevalence | 5 |
especially among | 5 |
probiotics may | 5 |
recognized disease | 5 |
blood sample | 5 |
contributed equally | 5 |
bactec blood | 5 |
laboratory tests | 5 |
puuv infections | 5 |
laboratory testing | 5 |
rsv prevalence | 5 |
confirmed imd | 5 |
heart rate | 5 |
like virus | 5 |
second week | 5 |
docking study | 5 |
diffuse bilateral | 5 |
critical illness | 5 |
mild upper | 5 |
patients showed | 5 |
iav lungs | 5 |
first blood | 5 |
regional hospital | 5 |
lung infiltrates | 5 |
proportional hazards | 5 |
meningococcal capsular | 5 |
demographic characteristics | 5 |
microbial infections | 5 |
fever cases | 5 |
clinical significance | 5 |
parylated protein | 5 |
human rhinovirus | 5 |
immune effect | 5 |
routine blood | 5 |
total number | 5 |
lymphocyte count | 5 |
human respiratory | 5 |
antifungal therapy | 5 |
bacterial counts | 5 |
beneficial effects | 5 |
poor prognosis | 5 |
dose corticosteroid | 5 |
ne cases | 5 |
chest radiography | 5 |
specific antibodies | 5 |
horizontal lines | 5 |
pcr tests | 5 |
observational cohort | 5 |
serologic test | 5 |
overall mortality | 5 |
diagnostic test | 5 |
recent studies | 5 |
signal reception | 5 |
underlying diseases | 5 |
meteorological conditions | 5 |
tract disease | 5 |
gray zone | 5 |
antiviral mechanisms | 5 |
fever outbreak | 5 |
streptococcus pyogenes | 5 |
vero cells | 5 |
saudi arabia | 5 |
clinical setting | 5 |
mild symptoms | 5 |
olaparib treatment | 5 |
multicenter study | 5 |
viral transport | 5 |
relatively high | 5 |
antimicrobial coatings | 5 |
affiliated hospital | 5 |
homozygous individuals | 5 |
ict assays | 5 |
sars virus | 5 |
european hantavirus | 5 |
genital lesions | 5 |
possible antiviral | 5 |
adults presenting | 5 |
study provided | 5 |
european union | 5 |
inhibitory activity | 5 |
negative nasopharyngeal | 5 |
induced acute | 5 |
culture analyser | 5 |
clinical criteria | 5 |
stomatitis virus | 5 |
resistant strains | 5 |
platelet counts | 5 |
peroxide vapour | 5 |
chinese center | 5 |
antiviral resistance | 5 |
broad spectrum | 5 |
laboratory reference | 5 |
internal positive | 5 |
suspected covid | 5 |
lactate dehydrogenase | 5 |
patients included | 5 |
lung homogenate | 5 |
conjugate vaccination | 5 |
etiologic agent | 5 |
patients underwent | 5 |
results suggest | 5 |
varying degrees | 5 |
patient outcomes | 5 |
reduced susceptibility | 5 |
antimicrobial agents | 5 |
least days | 5 |
determined using | 5 |
infective activities | 5 |
crude incidence | 5 |
standard deviations | 5 |
novel parvovirus | 5 |
antibacterially active | 5 |
saps ii | 5 |
abar receptor | 5 |
oral transmission | 5 |
weinberg equilibrium | 5 |
virus load | 5 |
serologic tests | 5 |
neutralizing antibodies | 5 |
accessory proteins | 5 |
positive serology | 5 |
infected individuals | 5 |
surface motility | 5 |
clinical suspicion | 5 |
high sensitivity | 5 |
commonly detected | 5 |
remaining patients | 5 |
balf samples | 5 |
one case | 5 |
severe disease | 5 |
asymptomatic patients | 5 |
cargico group | 5 |
converting enzyme | 5 |
gnb gram | 5 |
nosocomial strains | 5 |
supplemental oxygen | 5 |
glass opacities | 5 |
igm igg | 5 |
neurological symptoms | 5 |
toronto sars | 5 |
military recruits | 5 |
clinical evidence | 5 |
european consensus | 5 |
receptor concentration | 5 |
experimental studies | 5 |
therapeutic hypothermia | 5 |
sore throat | 5 |
infections due | 5 |
viral testing | 5 |
overall case | 5 |
institutional review | 5 |
failure assessment | 5 |
one positive | 5 |
southeastern china | 5 |
single nucleotide | 5 |
classical risk | 5 |
positive samples | 5 |
ref strains | 5 |
immune status | 5 |
respiratory droplets | 5 |
overnight culture | 5 |
initial assessment | 5 |
significantly longer | 5 |
close contact | 5 |
ct findings | 5 |
heart failure | 5 |
new york | 5 |
spanish population | 5 |
several limitations | 5 |
vesicular stomatitis | 5 |
infection without | 5 |
categorical data | 5 |
msg gene | 5 |
acute physiology | 5 |
patients died | 5 |
important factor | 5 |
resistant virus | 5 |
associated pathogens | 5 |
routine infant | 5 |
national immunization | 5 |
antibiotic prescription | 5 |
nic critically | 5 |
transplant patients | 5 |
body fluids | 5 |
prospective observational | 5 |
specific anti | 5 |
survival rate | 5 |
seven patients | 5 |
paramyxovirus infection | 5 |
three cases | 5 |
many studies | 5 |
cytokine storm | 5 |
multiple viruses | 5 |
microbial pathogens | 5 |
available data | 5 |
lung involvement | 5 |
human body | 5 |
microbiology laboratory | 5 |
renal replacement | 5 |
weeks prior | 5 |
bacterial pathogens | 5 |
mean wind | 5 |
complement system | 5 |
treatment program | 5 |
rs snp | 5 |
resulted negative | 5 |
ct scans | 5 |
total parenteral | 5 |
bacterial infection | 5 |
pulmonary oedema | 5 |
term positive | 5 |
haemorrhagic fever | 5 |
vasoactive support | 5 |
casei shirota | 5 |
lower rtis | 5 |
three days | 5 |
acquired bacterial | 5 |
burkholderia cepacia | 5 |
regression model | 5 |
human ace | 5 |
potential risk | 5 |
subsequent negative | 5 |
detected viruses | 5 |
standard curve | 5 |
respiratory rate | 5 |
new england | 5 |
room air | 5 |
viral detection | 5 |
less likely | 5 |
replacement therapy | 5 |
herd immune | 5 |
two consecutive | 5 |
may help | 5 |
antimicrobial treatment | 5 |
respiratory co | 5 |
patient required | 5 |
rsv detection | 5 |
tracheal aspirate | 5 |
fluorogenic rt | 5 |
polyomavirus bk | 5 |
pcr system | 5 |
specific probiotics | 5 |
monoclonal antibodies | 5 |
developing countries | 5 |
multivariable analyses | 5 |
human parvovirus | 5 |
throat swab | 5 |
high percentage | 5 |
working group | 5 |
parenteral nutrition | 5 |
steroid therapy | 5 |
four weeks | 5 |
index patient | 5 |
also compared | 5 |
soluble il | 5 |
acute upper | 5 |
institute inc | 5 |
crude mortality | 5 |
still controversial | 5 |
viral origin | 5 |
adults hospitalized | 5 |
like symptoms | 5 |
medical university | 5 |
time since | 5 |
ifng snps | 5 |
tissue damage | 5 |
ebv dna | 5 |
identifying patients | 5 |
pyocyanin production | 5 |
severe case | 5 |
dose corticosteroids | 5 |
significantly different | 5 |
pleural effusion | 5 |
days later | 5 |
clinical research | 5 |
epidemiological characteristics | 5 |
lateral flow | 5 |
negative sars | 5 |
ventilated patients | 5 |
clinically relevant | 5 |
outcome measures | 5 |
new onset | 5 |
serum endocan | 5 |
negative bacilli | 5 |
evidence suggests | 5 |
control practices | 5 |
th days | 5 |
suspected cases | 5 |
vast majority | 5 |
unknown etiology | 5 |
final manuscript | 5 |
clinical description | 5 |
health authorities | 5 |
high rates | 5 |
endocan levels | 5 |
positive rates | 5 |
wind speed | 5 |
human cells | 5 |
swab test | 5 |
antiviral agents | 5 |
pneumonia diagnosis | 5 |
limited data | 5 |
antiviral drugs | 5 |
disinfection system | 5 |
enteroviral meningitis | 5 |
four groups | 5 |
prothrombin time | 4 |
calculated using | 4 |
environmental survival | 4 |
significantly elevated | 4 |
iav mice | 4 |
calculated times | 4 |
done using | 4 |
nk cell | 4 |
clear halo | 4 |
sex ratio | 4 |
drug administration | 4 |
conjugate menacwy | 4 |
highly inhibited | 4 |
marco nofri | 4 |
acid detection | 4 |
bacteremic patients | 4 |
acquired infections | 4 |
venous hemodiafiltration | 4 |
resistance among | 4 |
broncho aspirations | 4 |
climate factors | 4 |
cell lineages | 4 |
last years | 4 |
two subsequent | 4 |
microbiological laboratory | 4 |
pulmonary fibrosis | 4 |
normal distribution | 4 |
recently published | 4 |
infection human | 4 |
relative expression | 4 |
immunomodulatory activity | 4 |
days pos | 4 |
patient groups | 4 |
conventional pcr | 4 |
forming units | 4 |
authors found | 4 |
phase ii | 4 |
another etiology | 4 |
convalescent serology | 4 |
psi score | 4 |
spectrum light | 4 |
empirical antibiotic | 4 |
hantavirus nephropathy | 4 |
frequently seen | 4 |
current literature | 4 |
seasonal patterns | 4 |
peroxide vapor | 4 |
wise comparisons | 4 |
also seen | 4 |
cells mm | 4 |
heavier consciousness | 4 |
qsis inhibited | 4 |
sera collected | 4 |
menc conjugate | 4 |
autoinducer synthase | 4 |
measured using | 4 |
commercial elisa | 4 |
whole blood | 4 |
frequent respiratory | 4 |
mean log | 4 |
several viruses | 4 |
healthy individuals | 4 |
fatal outcome | 4 |
came positive | 4 |
isac members | 4 |
clinical data | 4 |
developed new | 4 |
new textiles | 4 |
immunochromatographic tests | 4 |
emerging infection | 4 |
toxoplasma gondii | 4 |
master mix | 4 |
baumannii infections | 4 |
interim guidance | 4 |
rapid molecular | 4 |
extracted using | 4 |
dairy goat | 4 |
hospital inpatients | 4 |
fluoroquinolones inhibit | 4 |
samples tested | 4 |
fungal keratitis | 4 |
piv incidence | 4 |
median time | 4 |
plasma levels | 4 |
return positive | 4 |
single dose | 4 |
th day | 4 |
first affiliated | 4 |
developed countries | 4 |
symptom scores | 4 |
additive model | 4 |
diagnosis remains | 4 |
fermentum cect | 4 |
human participants | 4 |
rna viruses | 4 |
respiratory secretions | 4 |
andes virus | 4 |
protective effects | 4 |
hospital outbreak | 4 |
bocavirus infection | 4 |
additional cases | 4 |
associated hps | 4 |
within years | 4 |
first case | 4 |
clinical interpretation | 4 |
sab patients | 4 |
similar seasonal | 4 |
candidemia due | 4 |
strains isolated | 4 |
studies suggest | 4 |
relevant cultivable | 4 |
median score | 4 |
positive nucleic | 4 |
monthly mean | 4 |
antigenic drift | 4 |
aeruginosa ml | 4 |
affiliations acknowledgments | 4 |
cerebrovascular co | 4 |
bacterial cultures | 4 |
hantavirus species | 4 |
sin nombre | 4 |
anna gidari | 4 |
infected pneumonia | 4 |
violacein pigment | 4 |
infection among | 4 |
respiratory illnesses | 4 |
studies included | 4 |
hospitalized adult | 4 |
early stages | 4 |
trigeminal ganglia | 4 |
rna shedding | 4 |
viral diagnosis | 4 |
detailed information | 4 |
class iii | 4 |
intermediate hosts | 4 |
chlamydophila pneumoniae | 4 |
surveillance network | 4 |
odds ratios | 4 |
large outbreak | 4 |
syndrome hantavirus | 4 |
mechanisms underlying | 4 |
early phase | 4 |
white spanish | 4 |
virus pneumonia | 4 |
toronto area | 4 |
bilateral ground | 4 |
haematopoietic stem | 4 |
genome sequences | 4 |
bacterial burden | 4 |
human development | 4 |
comparative study | 4 |
epidemiological data | 4 |
supportive measures | 4 |
also collected | 4 |
care hospital | 4 |
clinical aspects | 4 |
capillary permeability | 4 |
significant decrease | 4 |
cell count | 4 |
antiviral drug | 4 |
cell wall | 4 |
elderly population | 4 |
new coronavirus | 4 |
pneumococcal meningitis | 4 |
protective role | 4 |
i interferon | 4 |
systematic use | 4 |
every year | 4 |
excluded cases | 4 |
continuous monitoring | 4 |
igm antibodies | 4 |
acute lower | 4 |
mortality among | 4 |
study populations | 4 |
important role | 4 |
acquired candidemia | 4 |
virus particles | 4 |
chloroquine showed | 4 |
prospective cohort | 4 |
acid derivatives | 4 |
baseline characteristics | 4 |
healthcare systems | 4 |
healthy immunocompetent | 4 |
syndrome due | 4 |
resistant organisms | 4 |
laboratory indexes | 4 |
respiratory pathogen | 4 |
recall bias | 4 |
molecular evolution | 4 |
positively correlated | 4 |
atypical lymphocytes | 4 |
creatinine level | 4 |
baloxavir marboxil | 4 |
cytopenias group | 4 |
first line | 4 |
recurrent positive | 4 |
acquired infection | 4 |
adverse events | 4 |
igg kit | 4 |
positive csf | 4 |
pleural effusions | 4 |
manage covid | 4 |
zoster virus | 4 |
clinical implications | 4 |
ml vs | 4 |
homoserine lactone | 4 |
burnetii infection | 4 |
substantial agreement | 4 |
using sas | 4 |
associated aspergillosis | 4 |
generalized additive | 4 |
pcr analysis | 4 |
defined according | 4 |
innate immunity | 4 |
poorly understood | 4 |
inhibitor resistance | 4 |
tertiary hospitals | 4 |
specific organ | 4 |
deceased patients | 4 |
biofilm forming | 4 |
absolute neutrophil | 4 |
transmission dynamics | 4 |
blood cell | 4 |
mean time | 4 |
az treatment | 4 |
copies per | 4 |
important cause | 4 |
swab samples | 4 |
vaccine effectiveness | 4 |
simplified acute | 4 |
prone children | 4 |
inner ring | 4 |
classified according | 4 |
hospital death | 4 |
respir viruses | 4 |
may reduce | 4 |
ct imaging | 4 |
abi prism | 4 |
higher rates | 4 |
days prior | 4 |
positive gm | 4 |
sample collected | 4 |
may cause | 4 |
study aimed | 4 |
confirmed case | 4 |
serological status | 4 |
differ significantly | 4 |
care centres | 4 |
severe sepsis | 4 |
lopinavir ritonavir | 4 |
bacterial culture | 4 |
hemophagocytic lymphohistiocytosis | 4 |
subtropical region | 4 |
animal studies | 4 |
different clinical | 4 |
clinical samples | 4 |
membrane oxygenation | 4 |
viral culture | 4 |
immunodiagnostic tests | 4 |
igm rapid | 4 |
observational retrospective | 4 |
three weeks | 4 |
echovirus type | 4 |
type bacteriophage | 4 |
direct exposure | 4 |
outer membrane | 4 |
preceding month | 4 |
pharyngeal swabs | 4 |
corticosteroids combined | 4 |
study found | 4 |
mpo levels | 4 |
probable pcp | 4 |
cases reported | 4 |
published studies | 4 |
associated coronavirus | 4 |
test covid | 4 |
index case | 4 |
swiss icus | 4 |
complement cascade | 4 |
qs inhibitory | 4 |
part due | 4 |
positive rate | 4 |
meningococcal vaccination | 4 |
requiring hospitalization | 4 |
care testing | 4 |
consensus definitions | 4 |
asterisk denotes | 4 |
serological response | 4 |
bordetella pertussis | 4 |
lactobacillus fermentum | 4 |
bacterial coinfections | 4 |
therapy prior | 4 |
quantitative variables | 4 |
like receptor | 4 |
fine clear | 4 |
immune dysregulation | 4 |
atypical pneumonia | 4 |
terminal complement | 4 |
oral lesions | 4 |
respiratory insufficiency | 4 |
risk adults | 4 |
noninvasive ventilation | 4 |
concentrations ranging | 4 |
severe symptoms | 4 |
high morbidity | 4 |
clinical scenario | 4 |
genome sequencing | 4 |
old children | 4 |
lag phase | 4 |
interstitial lung | 4 |
vegetative bacteria | 4 |
without sub | 4 |
cytokine signaling | 4 |
nbm groups | 4 |
inflammatory disorders | 4 |
patient rooms | 4 |
cytoplasmic inclusions | 4 |
intravascular coagulation | 4 |
np gene | 4 |
bilateral pleural | 4 |
income countries | 4 |
dose response | 4 |
viral particles | 4 |
children attending | 4 |
climatic factors | 4 |
common mode | 4 |
disseminated candidiasis | 4 |
rhamnosus lc | 4 |
lung homogenates | 4 |
kidney disease | 4 |
without qsis | 4 |
across groups | 4 |
genome sequence | 4 |
icu hospitalization | 4 |
multiplex reverse | 4 |
care workers | 4 |
patient presented | 4 |
arterial blood | 4 |
synthesis kit | 4 |
virus isolation | 4 |
antibiotic administration | 4 |
detected among | 4 |
infection date | 4 |
endemic areas | 4 |
clinical settings | 4 |
independent variable | 4 |
clinical illness | 4 |
abdominal pain | 4 |
kidney cells | 4 |
european countries | 4 |
antifungal agents | 4 |
remains unclear | 4 |
transplant recipient | 4 |
dna polymerase | 4 |
assessed using | 4 |
zagazig university | 4 |
hightouch surfaces | 4 |
second group | 4 |
presenting cells | 4 |
hydroxyl radical | 4 |
rapid viral | 4 |
surgical patients | 4 |
murine models | 4 |
chemoregulation loss | 4 |
clinically effective | 4 |
nasopharyngeal aspirates | 4 |
pigment production | 4 |
mortality rates | 4 |
immunofluorescent assay | 4 |
detected using | 4 |
step treatment | 4 |
environmental decontamination | 4 |
protease activity | 4 |
confirmed patients | 4 |
alanine aminotransferase | 4 |
first days | 4 |
reactive oxygen | 4 |
data analysis | 4 |
case reports | 4 |
well known | 4 |
economic burden | 4 |
almost identical | 4 |
lower ct | 4 |
also reported | 4 |
innate immune | 4 |
virus population | 4 |
per milliliter | 4 |
infection presentation | 4 |
healthcare personnel | 4 |
correlation coefficient | 4 |
prophylactic anticoagulation | 4 |
lb medium | 4 |
within hours | 4 |
rapid test | 4 |
otherwise healthy | 4 |
nucleotide polymorphisms | 4 |
lower limit | 4 |
different human | 4 |
throat swabs | 4 |
candida parapsilosis | 4 |
human kidney | 4 |
clinical microbiology | 4 |
patients suffering | 4 |
first hospital | 4 |
known case | 4 |
among inpatients | 4 |
persistent viral | 4 |
cns diseases | 4 |
per minute | 4 |
attack rates | 4 |
patients whose | 4 |
antiviral effect | 4 |
air circulation | 4 |
less frequently | 4 |
urgently needed | 4 |
virus may | 4 |
analysed using | 4 |
flow cytometry | 4 |
rate min | 4 |
first positive | 4 |
attending day | 4 |
compare medians | 4 |
baumannii clinical | 4 |
homogeneous cytoplasmic | 4 |
presenting symptoms | 4 |
hospital cleaning | 4 |
many reports | 4 |
continuous veno | 4 |
fermented dairy | 4 |
patients hospitalized | 4 |
enzyme immunoassay | 4 |
identified cases | 4 |
open access | 4 |
health burden | 4 |
apicoplast dna | 4 |
detection among | 4 |
males females | 4 |
sars transmission | 4 |
helsinki declaration | 4 |
highest number | 4 |
physiology score | 4 |
binding affinity | 4 |
menacwy vaccination | 4 |
invasive neisseria | 4 |
low replication | 4 |
higher apache | 4 |
liver cirrhosis | 4 |
viral pathogen | 4 |
lung diseases | 4 |
bactericidal activity | 4 |
double dose | 4 |
considered significant | 4 |
many factors | 4 |
detection system | 4 |
severe symptomatic | 4 |
care center | 4 |
prospective evaluation | 4 |
human macrophages | 4 |
inhibitory concentration | 4 |
mortality risk | 4 |
one common | 4 |
test cassette | 4 |
environmental disinfection | 4 |
patient received | 4 |
igm positive | 4 |
greenish homogeneous | 4 |
possibly via | 4 |
higher incidence | 4 |
adaptive immunity | 4 |
fisher exact | 4 |
swine influenza | 4 |
recently reported | 4 |
spectrum antibiotics | 4 |
first step | 4 |
common pathogen | 4 |
excluded sars | 4 |
carbon dioxide | 4 |
level disinfection | 4 |
lines compare | 4 |
variant rs | 4 |
medians across | 4 |
serological test | 4 |
influenza pneumonia | 4 |
sars infection | 4 |
greater among | 4 |
diagnostic tool | 4 |
influenza diagnosis | 4 |
care centers | 4 |
genes involved | 4 |
specific antibody | 4 |
survival rates | 4 |
authors read | 4 |
testing positive | 4 |
clinical laboratory | 4 |
rna polymerase | 4 |
wound infections | 4 |
intensity narrow | 4 |
analyzed using | 4 |
patient developed | 4 |
antifungal treatment | 4 |
evolutionary rate | 4 |
rapid antigen | 4 |
optimal cut | 4 |
retrospective review | 4 |
copy numbers | 4 |
old male | 4 |
may influence | 4 |
reproduction number | 4 |
primary medical | 4 |
term sars | 4 |
bilateral infiltrates | 4 |
false positives | 4 |
presumptive recurrence | 4 |
high incidence | 4 |
inhibitor resistant | 4 |
induced pneumonia | 4 |
less severe | 4 |
clinical care | 4 |
hmpv infection | 4 |
treatment algorithm | 4 |
lowest inhibition | 4 |
community hospital | 3 |
newly discovered | 3 |
multiple viral | 3 |
class i | 3 |
research team | 3 |
adults aged | 3 |
received corticosteroids | 3 |
failure requiring | 3 |
successful treatment | 3 |
class ii | 3 |
four qsis | 3 |
causal relationship | 3 |
study involving | 3 |
children rapid | 3 |
dimer levels | 3 |
inspired oxygen | 3 |
disease outbreak | 3 |
squared test | 3 |
cycle threshold | 3 |
frequent detection | 3 |
proteolytic activity | 3 |
appropriate antimicrobial | 3 |
study human | 3 |
also available | 3 |
automated immunoassays | 3 |
acute infection | 3 |
seasonal effects | 3 |
coma scale | 3 |
mers coronavirus | 3 |
cellular immunity | 3 |
original author | 3 |
results confirmed | 3 |
mean evolutionary | 3 |
piv prevalence | 3 |
time points | 3 |
participating hospitals | 3 |
copan italia | 3 |
less well | 3 |
temporal bone | 3 |
winter seasons | 3 |
highly effective | 3 |
graphpad prism | 3 |
radiological progression | 3 |
nose infection | 3 |
without respiratory | 3 |
comprehensive review | 3 |
antiviral agent | 3 |
frequent cause | 3 |
targeted therapy | 3 |
anhui medical | 3 |
genetic analysis | 3 |
expression levels | 3 |
hospital rooms | 3 |
patients diagnosed | 3 |
laboratory confirmed | 3 |
combination antibiotic | 3 |
fatality rates | 3 |
patients receiving | 3 |
antifungal drugs | 3 |
detection methods | 3 |
human immune | 3 |
infiltrative lung | 3 |
sorlandet hospital | 3 |
also found | 3 |
normal left | 3 |
hcv rna | 3 |
pregnant woman | 3 |
protects mice | 3 |
probably due | 3 |
cytopenias affecting | 3 |
mental health | 3 |
days vs | 3 |
etiological agent | 3 |
mxa expression | 3 |
literature review | 3 |
structural proteins | 3 |
classified patients | 3 |
clinical perspective | 3 |
pathogenic avian | 3 |
strain isolated | 3 |
extreme caution | 3 |
factors including | 3 |
travel restrictions | 3 |
three hospitals | 3 |
optical density | 3 |
two points | 3 |
coagulation parameters | 3 |
type phages | 3 |
intracranial hypertension | 3 |
lactobacillus gg | 3 |
macrolide antibiotics | 3 |
strain kj | 3 |
campaign targeting | 3 |
mice fed | 3 |
plasmodium spp | 3 |
interstitial pneumonia | 3 |
healthcare system | 3 |
vapor pressure | 3 |
three stages | 3 |
kg olaparib | 3 |
growth inhibition | 3 |
unit patients | 3 |
high viral | 3 |
triple detections | 3 |
total sofa | 3 |
glasgow coma | 3 |
sole pathogen | 3 |
tract samples | 3 |
acute disseminated | 3 |
caucasian patients | 3 |
affiliations acknowledgements | 3 |
san diego | 3 |
studies also | 3 |
secular trend | 3 |
human parainfluenza | 3 |
young patients | 3 |
data collected | 3 |
sars epidemic | 3 |
global dissemination | 3 |
intracranial pressure | 3 |
moderate activity | 3 |
healthcare setting | 3 |
care items | 3 |
meteorological factors | 3 |
multivariate binomial | 3 |
surface cleaning | 3 |
cancer center | 3 |
least three | 3 |
meningococcal group | 3 |
inhibition zone | 3 |
provide insight | 3 |
based surveillance | 3 |
model using | 3 |
mild covid | 3 |
meny disease | 3 |
i ifn | 3 |
epidemic disease | 3 |
igm iga | 3 |
positive pj | 3 |
immunocompetent individuals | 3 |
required hospital | 3 |
em structure | 3 |
global warming | 3 |
three viruses | 3 |
antibody production | 3 |
immunomodulatory therapy | 3 |
tested using | 3 |
cerebral vasoreactivity | 3 |
northern europeans | 3 |
emerging infectious | 3 |
fluid samples | 3 |
pneumonia severity | 3 |
received oseltamivir | 3 |
peroxide decontamination | 3 |
previous infection | 3 |
formal consent | 3 |
prevent nosocomial | 3 |
interferon gamma | 3 |
specific incidence | 3 |
routine use | 3 |
resistance mutations | 3 |
viral fitness | 3 |
inhibited qs | 3 |
relevant outcomes | 3 |
testing results | 3 |
ipc rna | 3 |
hydroxychloroquine plus | 3 |
immunomodulatory activities | 3 |
study enrolment | 3 |
highly pathogenic | 3 |
frequent co | 3 |
higher probability | 3 |
compatible clinical | 3 |
elevated igm | 3 |
using pcr | 3 |
well plate | 3 |
became available | 3 |
emerging viral | 3 |
symptom data | 3 |
creatine kinase | 3 |
left ventricular | 3 |
sedimentation rate | 3 |
swab tests | 3 |
two fatal | 3 |
changing epidemiology | 3 |
cepacia complex | 3 |
following days | 3 |
search terms | 3 |
seasonal peaks | 3 |
total rna | 3 |
age distribution | 3 |
freudenreichii ssp | 3 |
using graphpad | 3 |
therapeutic plasma | 3 |
monovariate analysis | 3 |
different stages | 3 |
dna cleavage | 3 |
admission due | 3 |
wide spectrum | 3 |
highly variable | 3 |
levofloxacin pretreatment | 3 |
breath holding | 3 |
umbria region | 3 |
lung index | 3 |
relevant data | 3 |
methylprednisolone treatment | 3 |
recipient strain | 3 |
variables associated | 3 |
herd protection | 3 |
study including | 3 |
study whether | 3 |
maltese population | 3 |
environment surfaces | 3 |
neonates born | 3 |
coding sequences | 3 |
pneumocystis colonization | 3 |
function tests | 3 |
developed sars | 3 |
probiotic therapy | 3 |
influenza infections | 3 |
authors thank | 3 |
patients clinical | 3 |
medical resources | 3 |
fungal disease | 3 |
absolute value | 3 |
mononuclear cell | 3 |
western russia | 3 |
care hospitals | 3 |
seeplex rv | 3 |
may provide | 3 |
diseases caused | 3 |
chart review | 3 |
burnetii dose | 3 |
disease observed | 3 |
phylogenetic analysis | 3 |
last four | 3 |
erythromycin showed | 3 |
bodily fluids | 3 |
take place | 3 |
patients using | 3 |
continuous data | 3 |
tract viruses | 3 |
viral genomes | 3 |
circulating cytokines | 3 |
patient nos | 3 |
bed rooms | 3 |
infectious sars | 3 |
contact history | 3 |
studies showed | 3 |
sterile phosphate | 3 |
collected included | 3 |
cellular entry | 3 |
multiorgan failure | 3 |
ill adult | 3 |
thermofisher scientific | 3 |
antibacterial agent | 3 |
selection pressure | 3 |
transcriptase pcr | 3 |
respondents reported | 3 |
candida species | 3 |
successful recovery | 3 |
older patients | 3 |
annual epidemiological | 3 |
worse outcome | 3 |
two cut | 3 |
neutralizing antibody | 3 |
hospital universitario | 3 |
respiratory alkalosis | 3 |
correlation analysis | 3 |
major surface | 3 |
positivity rates | 3 |
codon site | 3 |
also increased | 3 |
blood lymphocytes | 3 |
petri dish | 3 |
new viruses | 3 |
resistant bacteria | 3 |
adults respiratory | 3 |
high titers | 3 |
immunocompromised individuals | 3 |
dependent variable | 3 |
ag combination | 3 |
positive qsi | 3 |
circulating strain | 3 |
human rhinoviruses | 3 |
structure analysis | 3 |
surveillance data | 3 |
culture vials | 3 |
including fever | 3 |
specific cytotoxic | 3 |
short time | 3 |
blood stream | 3 |
investigate whether | 3 |
previously mentioned | 3 |
parp inhibitors | 3 |
descriptive analysis | 3 |
different assays | 3 |
conjunctival specimens | 3 |
new zealand | 3 |
blood mononuclear | 3 |
intraperitoneally injected | 3 |
required mechanical | 3 |
mean air | 3 |
pathogens causing | 3 |
deficient mice | 3 |
vs days | 3 |
inconclusive rt | 3 |
infected mice | 3 |
outcome compared | 3 |
iaa influenza | 3 |
medical records | 3 |
outcome variable | 3 |
intravascular coagulopathy | 3 |
twice daily | 3 |
gm measured | 3 |
also analyzed | 3 |
acute exacerbations | 3 |
cell infiltrates | 3 |
well documented | 3 |
mortality test | 3 |
ten sets | 3 |
liposomal amphotericin | 3 |
fatigue syndrome | 3 |
hantavirus study | 3 |
south korea | 3 |
specific viruses | 3 |
binding site | 3 |
viral agents | 3 |
proteus mirabilis | 3 |
chest computed | 3 |
serologic diagnosis | 3 |
mortality worldwide | 3 |
team members | 3 |
one symptom | 3 |
ncov pneumonia | 3 |
clinical improvement | 3 |
blood isolates | 3 |
north america | 3 |
care medicine | 3 |
skimmed milk | 3 |
body weight | 3 |
severe outcome | 3 |
icu setting | 3 |
gramnegative bacteria | 3 |
significant reduction | 3 |
blood specimens | 3 |
ifn response | 3 |
igm detection | 3 |
bd bactec | 3 |
correctly classified | 3 |
might also | 3 |
inhibitory concentrations | 3 |
incubation period | 3 |
menb vaccine | 3 |
clear benefit | 3 |
viral dna | 3 |
overall crude | 3 |
specific clinical | 3 |
elevated serum | 3 |
commons licence | 3 |
capillary leakage | 3 |
genomes project | 3 |
microtiter plates | 3 |
three different | 3 |
neuroinvasive hsv | 3 |
hospital environmental | 3 |
logarithmic regression | 3 |
rheumatoid arthritis | 3 |
menb carriage | 3 |
tract diseases | 3 |
literature date | 3 |
development index | 3 |
negative cases | 3 |
one hematological | 3 |
patients required | 3 |
nasopharyngeal sampling | 3 |
prognostic value | 3 |
pathological findings | 3 |
menacwy conjugate | 3 |
pcr methods | 3 |
circulating peptides | 3 |
probiotic supplementation | 3 |
rapid tests | 3 |
pneumonia outbreak | 3 |
specific igg | 3 |
influenza resistance | 3 |
histoplasma capsulatum | 3 |
outer ring | 3 |
proteins including | 3 |
patients developed | 3 |
inhibitor susceptibility | 3 |
illness severity | 3 |
per patient | 3 |
sialic acid | 3 |
descriptive statistics | 3 |
oropharyngeal swabs | 3 |
known risk | 3 |
fever fatigue | 3 |
reference number | 3 |
downward trend | 3 |
microbiological methods | 3 |
urea nitrogen | 3 |
final volume | 3 |
factors contributing | 3 |
plasma samples | 3 |
reference unit | 3 |
takes place | 3 |
fecal matter | 3 |
jirovecii pneumonia | 3 |
vancomycin resistance | 3 |
heptad repeat | 3 |
colony diameter | 3 |
kidney function | 3 |
strip assays | 3 |
interferon production | 3 |
exposure history | 3 |
united nations | 3 |
elderly people | 3 |
included patients | 3 |
nic group | 3 |
two experienced | 3 |
critical covid | 3 |
pilot study | 3 |
significantly increased | 3 |
laboratory confirmation | 3 |
diagnostic evaluation | 3 |
eligibility criteria | 3 |
findings indicate | 3 |
underlying disease | 3 |
requiring prolonged | 3 |
viral meningitis | 3 |
preprint study | 3 |
opportunistic infections | 3 |
bacteremic groups | 3 |
iv pili | 3 |
well described | 3 |
outcome requiring | 3 |
third international | 3 |
mouse model | 3 |
test probability | 3 |
nasal swabs | 3 |
severe community | 3 |
age years | 3 |
discovered human | 3 |
current symptoms | 3 |
remained untypable | 3 |
least absolute | 3 |
experimental day | 3 |
organ transplantation | 3 |
vascular endothelium | 3 |
three paramyxoviruses | 3 |
common colds | 3 |
contact time | 3 |
complete blood | 3 |
induced meningitis | 3 |
recovered patients | 3 |
important respiratory | 3 |
white blood | 3 |
included fever | 3 |
cairo university | 3 |
individual patients | 3 |
elevated il | 3 |
distilled water | 3 |
bacterial superinfection | 3 |
antibody detection | 3 |
rapid diagnosis | 3 |
remained significantly | 3 |
hospital setting | 3 |
allele frequency | 3 |
systemic fungal | 3 |
sequence analysis | 3 |
performed two | 3 |
patients requiring | 3 |
selection operator | 3 |
similar clinical | 3 |
ict strip | 3 |
symptomatic individuals | 3 |
olaparib decreased | 3 |
contaminated hts | 3 |
laboratory data | 3 |
limiting upper | 3 |
retrospective observational | 3 |
small retrospective | 3 |
hps patients | 3 |
rhesus macaques | 3 |
lung inflammatory | 3 |
viral diagnostic | 3 |
human specimens | 3 |
epidemiological report | 3 |
persistent bacteremia | 3 |
high proportion | 3 |
prolonged hospitalisation | 3 |
immunization schedule | 3 |
cell membrane | 3 |
bone metabolism | 3 |
presented two | 3 |
international society | 3 |
patient characteristics | 3 |
mice infected | 3 |
wuhan huanan | 3 |
blood urea | 3 |
pneumococcal infections | 3 |
globally emerging | 3 |
angiotensin ii | 3 |
involving pulmonary | 3 |
trial coordination | 3 |
urinary antigen | 3 |
pulmonary artery | 3 |
treatment duration | 3 |
antibacterial activities | 3 |
infected cells | 3 |
protection conferred | 3 |
fungal cultures | 3 |
unexplained bilateral | 3 |
better understand | 3 |
identified using | 3 |
qualitative variables | 3 |
regression analyses | 3 |
igg detection | 3 |
negative respiratory | 3 |
mean overall | 3 |
following criteria | 3 |
tract illnesses | 3 |
microbial adhesion | 3 |
also demonstrated | 3 |
biological specimens | 3 |
case records | 3 |
perihilar infiltrates | 3 |
air pressure | 3 |
long time | 3 |
inhaled zanamivir | 3 |
systemic candidiasis | 3 |
selected patients | 3 |
three tertiary | 3 |
severe cardiopulmonary | 3 |
community transmission | 3 |
higher concentrations | 3 |
menacwy dose | 3 |
disseminated encephalomyelitis | 3 |
study suggests | 3 |
different age | 3 |
three subjects | 3 |
via rt | 3 |
three cell | 3 |
may persist | 3 |
host genetics | 3 |
acute otitis | 3 |
plastic dishes | 3 |
sensing inhibitors | 3 |
elisa euroimmun | 3 |
ray showed | 3 |
fluorescence rate | 3 |
nursing home | 3 |
infections without | 3 |
serum potassium | 3 |
inflammatory cell | 3 |
advisory committee | 3 |
negative balf | 3 |
important causes | 3 |
disease patients | 3 |
intravenous immunoglobulin | 3 |
analysis based | 3 |
worsening respiratory | 3 |
meningitis strains | 3 |
clinical information | 3 |
showed significant | 3 |
pneumocystis carinii | 3 |
done within | 3 |
infections among | 3 |
blurred vision | 3 |
multiple organ | 3 |
bacterial superinfections | 3 |
baumannii strain | 3 |
year old | 3 |
preterm infants | 3 |
hantavirus cardiopulmonary | 3 |
virus laboratory | 3 |
inflammatory diseases | 3 |
mean crude | 3 |
severe asthma | 3 |
similar cases | 3 |
outcome defined | 3 |
thoracic pain | 3 |
bk infection | 3 |
stratified according | 3 |
enterovirus rna | 3 |
vs sab | 3 |
mice mortality | 3 |
without renal | 3 |
among cases | 3 |
patients testing | 3 |
among healthcare | 3 |
examination showed | 3 |
widespread dissemination | 3 |
significantly inhibited | 3 |
sporadic cases | 3 |
systemic inflammatory | 3 |
system infections | 3 |
time interval | 3 |
iga titre | 3 |
one swab | 3 |
whether patients | 3 |
double blind | 3 |
ahl signal | 3 |
virological persistence | 3 |
studied compounds | 3 |
selection site | 3 |
may occur | 3 |
oropharyngeal candidiasis | 3 |
significant morbidity | 3 |
atypical presentations | 3 |
clinical assessment | 3 |
general spanish | 3 |
inflammatory effect | 3 |
ocular manifestations | 3 |
amniotic fluid | 3 |
may lead | 3 |
reaction assay | 3 |
neonatal serum | 3 |
selection bias | 3 |
iga positive | 3 |
marrow transplant | 3 |
pa i | 3 |
medical conditions | 3 |
molecular basis | 3 |
virus dna | 3 |
might explain | 3 |
inhibitor olaparib | 3 |
regional virus | 3 |
died due | 3 |
phage lysate | 3 |
cell infiltration | 3 |
clinical variables | 3 |
phe laboratory | 3 |
bal macrophages | 3 |
colonization among | 3 |
cooled pbs | 3 |
local transmission | 3 |
physical examination | 3 |
children hospitalized | 3 |
patients homozygous | 3 |
buffered saline | 3 |
recent report | 3 |
hospital day | 3 |
hazard ratio | 3 |
obtained using | 3 |
patients identified | 3 |
inflammatory infiltrates | 3 |
hospital admissions | 3 |
coronavirus oc | 3 |
intermediate stage | 3 |
temporal pattern | 3 |
dna assays | 3 |
tracheal epithelial | 3 |
bacterial co | 3 |
oxygen therapy | 3 |
individuals receiving | 3 |
bactericidal antibody | 3 |
shermanii js | 3 |
vp gene | 3 |
approved drugs | 3 |
one isolate | 3 |
large numbers | 3 |
population level | 3 |
gran canaria | 3 |
echocardiography showed | 3 |
endothelial cell | 3 |
cryptococcus neoformans | 3 |
funding information | 3 |
overall study | 3 |
positive bal | 3 |
without aminoglycosides | 3 |
underlying mechanisms | 3 |
qs inhibition | 3 |
mean vapor | 3 |
viral antigens | 3 |
detection limit | 3 |
social panic | 3 |
icu support | 3 |
chest imaging | 3 |
endotracheal intubation | 3 |
prognostic factor | 3 |
low burden | 3 |
cultivable microorganisms | 3 |
breve bb | 3 |
medical care | 3 |
atypical bacteria | 3 |
study demonstrated | 3 |
antifungal activities | 3 |
specific antiviral | 3 |
cell responses | 3 |
medical pathology | 3 |
may exist | 3 |
nosocomial respiratory | 3 |
future studies | 3 |
dna gyrase | 3 |
different environmental | 3 |
recent advances | 3 |
influenza surveillance | 3 |
negative pharyngeal | 3 |
first cases | 3 |
full ppe | 3 |
significant higher | 3 |
etiologic agents | 3 |
growth curves | 3 |
primary care | 3 |
negative patients | 3 |
induced mortality | 3 |
yichang central | 3 |
pregnant mothers | 3 |
evolutionary rates | 3 |
bacteraemia secondary | 3 |
oxygen saturation | 3 |
reported symptom | 3 |
flow velocities | 3 |